Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06366217 · ClinicalTrials.gov registry record · Phase 4
Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients
A Phase 4 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT06366217 is a Phase 4 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 100 participants.
The verdict
NCT06366217, a Phase 4 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.
Interventions
- DEVICE MydCombi Device
- DRUG MydCombi Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06366217
The ClinicalTrials.gov registry entry for NCT06366217 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MydCombi Device is the first listed.
NCT06366217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06366217 about?
NCT06366217 is a clinical study titled "Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients". To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient...
What is the current status of trial NCT06366217?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2024-09-30. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT06366217?
The interventions under investigation include: MydCombi Device (DEVICE), MydCombi Drug (DRUG).
Who is sponsoring clinical trial NCT06366217?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.